The effect of the potent inhibitor of cholesterol absorption, ezetimibe, on serum cholesterol levels was tested in diabetic and thyroidectomized male Sprague-Dawley rats. Feeding diets supplemented with 1% cholesterol to the diabetic rats raised serum cholesterol levels from 132 to 514 mg/dl while decreasing hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase protein and mRNA levels. Addition of 10 mg/kg/day of ezetimibe to the diets of these animals lowered the serum cholesterol level to 90 mg/dl and produced a large compensatory increase in hepatic HMG-CoA reductase protein without significantly increasing mRNA levels, indicating a post-transcriptional effect. Hepatic LDL receptor protein levels in these diabetic rats were unaffected by ezetimibe treatment. In contrast, ezetimibe treatment of these young normal Sprague-Dawley rats, known to express high levels of hepatic HMG-CoA reductase, did not lower serum cholesterol levels. In thyroidectomized rats, dietary cholesterol increased serum cholesterol levels from 116 to 135 mg/dl and ezetimibe treatment lowered these elevated cholesterol levels to 85 mg/dl. Cholesterol feeding of thyroidectomized rats severely reduced hepatic HMG-CoA reductase protein, while ezetimibe treatment restored reductase protein to normal levels. Again, hepatic LDL receptor protein levels were unaffected by ezetimibe treatment of cholesterol-fed thyroidectomized rats. The data demonstrate that the cholesterol absorption inhibitor ezetimibe profoundly lowers serum cholesterol levels in animals expressing very low rates of hepatic cholesterol synthesis and produces large compensatory increases in hepatic HMG-CoA reductase expression without significantly affecting expression of hepatic LDL receptors. This indicates that ezetimibe should be most effective in lowering serum cholesterol levels in people with low rates of cholesterol synthesis/high rates of cholesterol absorption.
NessGC. Cholesterol homeostasis. In: FlielslerSJ, Ed. Sterols and Oxysterols: Chemistry, Biology and Pathobiology, Recent Research Developments in Biochemistry Series. Kerala, India: Research Signposts, pp 1–14, 2002.
2.
MiettinenTA, StrandbergTE, GyllingH, for the Finnish Investigators of the Scandinavian Simvastatin Survival Study Group.Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol. 20: 1340–1346, 2000.
3.
NessGC, ChambersCM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Exp Biol Med224: 8–19, 2000.
4.
NessGC. Physiological and pharmacological regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. In: Pape M, ed. Current Medicinal Chemistry—Immunology, Endocrine and Metabolic Agents. Bentham Science Publishers Ltd3: 219–227, 2003.
NessGC, ZhaoZ, LopezD. Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch Biochem Biophys325: 242–248, 1996.
7.
GrundySM, CleemanJI, MerzCNB, BrewerHBJr., ClarkLT, HunninghakeDB, PasternakRC, SmithSC, StoneNJ, for the Coordinating Committee of the National Cholesterol Education Program.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am. Coll Cardiol44: 720–732, 2004.
8.
CannonCP, BraunwaldE, McCabeCH, RaderDJ, RouleauJL, BelderR, JoyalSV, HillKA, PfefferMA, SkeneAM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med350: 1495–1504, 2004.
9.
LipkaL, SagerP, StronyJ, YangB, SureshR, VeltriE, Ezetimibe Study Group. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging21: 1025–1032, 2004.
10.
MurdochD, ScottLI. Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. Am J Cardiovasc Drugs4: 405–422, 2004.
11.
LindS, OlssonAG, ErikssonM, RudlingM, EggertsenG, AngelinB. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med256: 406–412, 2004.
12.
SimonsL, TonkonM, MasanaL, MaccubbinD, ShahA, LeeM, GumbinerB. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin20: 1437–1445, 2004.
13.
SteinE, StenderS, MataP, SagerP, PonsonnetD, MelaniL, LipkaL, SureshR, MaccubbinD, VeltriE, Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe coadministered with atorvastatin. Am Heart J148: 447–455, 2004.
14.
DavidsonMH, BallantyneCM, KerznerB, MelaniL, SagerPT, LipkaL, StronyJ, SureshR, VeltriE, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract58: 746–755, 2004.
15.
BallantyneCM, BlazingMA, KingTR, BradyWE, PalmisanoJ. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol93: 1487–1494, 2004.
16.
FeldmanT, KorenM, InsullWJr., McKenneyJ, SchrottH, LewinA, ShahS, SidisinM, ChoM, KushD, MitchelY. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol93: 1481–1486, 2004.
BaysHE, OseL, FraserN, TribbleDL, QuintoK, ReyesR, Johnson-LevonasAO, SapreA, DonahueSR, Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther26: 1758–1773, 2004.
19.
DavisHR, PulaKK, AltonKB, BurnerRE, WatkinsRW. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3. methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism50: 1234–1241, 2001.
20.
RepaJJ, TurleySD, QuanG, DietschyJM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res46: 779–789, 2005.
21.
NessGC, GertzKR. Increased sensitivity to dietary cholesterol in diabetic and hypothyroid rats associated with low levels of hepatic HMG-CoA reductase expression. Exp Biol Med229: 407–411, 2004.
22.
MiettinenTA, GyllingH, TuominenJ, SimonenP, KoivistoV. Low synthesis and high absorption of cholesterol characterize type I diabetes. Diabetes Care27: 53–58, 2004.
23.
GyllingH, TuominenJA, KoivistoVA, MiettinenTA. Cholesterol metabolism in type I diabetes. Diabetes53: 2217–2222, 2004.
24.
IllingworthD, McClungMR, ConnerWE, AlaupovicP. Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. Clin Endocrinol14: 145–152, 1981.
25.
NessGC. Thyroid hormone: basis for its hypocholesterolemic effect. J Fla Med Assoc78: 383–385, 1991.
NessGC, GertzKR, HollandRC. Regulation of hepatic lanosterol 14α demethylase gene expression by dietary cholesterol and cholesterol-lowering agents. Arch Biochem Biophys395: 233–238, 2001.
28.
NessGC, GertzKR. Increased sensitivity to dietary cholesterol in diabetic and hypothyroid rats associated with low levels of hepatic HMG-CoA reductase expression. Exp Biol Med229: 407–411, 2004.
29.
YuL, von BergmannK, LutjohannD, HobbsHH, CohenJC. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J Lipid Res46: 1739–1744, 2005.
30.
LagorWR, de GrohED, NessGC. Diabetes alters the occupancy of the hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase promoter. J Biol Chem280: 36601–36608, 2005.
31.
NessGC, KellerRK, PendletonLC. Feedback regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by dietary cholesterol is not due to altered mRNA levels. J Biol Chem266: 14854–14857, 1991.
ChambersCM, NessGC. Dietary cholesterol regulates hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in rats primarily at the level of translation. Arch Biochem Biophys354: 317–322, 1998.
34.
NessGC, HollandRC. Degradation of HMG-CoA reductase in rat liver is cholesterol and ubiquitin independent. FEBS Letters579: 3126–3130, 2005.
35.
ChambersCM, NessGC. Translational regulation of hepatic HMG-CoA reductase by dietary cholesterol. Biochem Biophys Res Commun232: 278–281, 1997.
36.
VallettSM, SanchezHB, RosenfeldJM, OsborneTF. A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J Biol Chem271: 12247–12253, 1996.
37.
BrownMS, GoldsteinJL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A96: 11041–11048, 1999.
38.
HortonJD, GoldsteinJL, BrownMS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest109: 1125–1131, 2002.
39.
EngelkingLJ, LiangG, HammerRE, TakaishiK, KuriyamaH, EversBM, LiW-P, HortonJD, GoldsteinJL, BrownMS. Schoenheimer effect explained—feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest115: 2489–2498, 2005.
40.
GrafGA, YuL, LiW-P, GerardR, TumaPL, CohenJC, HobbsHH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem278: 48275–48282, 2003.
41.
YuL, GuptaS, XuF, LivermanADB, MoschettaA, MangelsdorfDJ, RepaJJ, HobbsHH, CohenJC. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem280: 8742–8747, 2005.
42.
YuL, von BergmannK, LutjohannD, HobbsHH, CohenJC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res45: 301–307, 2004.
43.
PihlajamakiJ, GyllingH, MiettinenTA, LaaksoM. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res45: 507–512, 2003.
44.
GyllingH, TuominenJA, KoivistoVA, MiettinenTA. Cholesterol metabolism in type 1 diabetes. Diabetes53: 2217–2222, 2004.
45.
AltmannSW, DavisHRJr., ZhuL-J, YaoX, HoosLM, TetzloffG, IyerSPN, MaguireM, GolovkoA, ZengM, WangL, MurgoloN, GrazianoMP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science303: 1201–1204, 2004.
46.
DavisHRJr., ZhuL-J, HoosLM, TetzloffG, MaguireM, KiuJ, YaoX, IyerSPN, LamM-H, LundEG, DetmersPA, GrazianoMP, AltmannSW. Niemann-Pick CI Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem279: 33586–33592, 2004.
47.
IyerSPN, YaoX, CronaJH, HoosLM, TetzloffG, DavisHRJr., GrazianoMP, AltmannSW. Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim Biophys Acta1722: 282–292, 2005.
48.
Garcio-CalvoM, LisnockJM, BullHG, HawesBE, BurnettDA, BraunMP, CronaJH, DavisHRJr., DeanDC, DetmersPA, GrazianoMP, HughesM, MaclntyreDE, OgawaA, O'neillKA, IyerSPN, ShevellDE, SmithMM, TangYS, MakarewiczAM, UjjainwallaF, AltmannSW, ChapmanKT, ThomberryNA. The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1). Proc Natl Acad Sci U S A102: 8132–8137, 2005.
49.
ValasekMA, WengJ, ShaulPW, AndersonRGW, RepaJJ. Caveolin-1 is not required for murine intestinal cholesterol transport. J Biol Chem280: 28103–28109, 2005.
50.
SmartEJ, De RoseRA, FarberSA. Annexin 2–caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc Natl Acad Sci U S A101: 3450–3455, 2004.
51.
CohenJC, PertsemlidisA, FahmiS, EsmailS, VegaGL, GrundySM, HobbsHH. Multiple rare variants in NPCIL1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci U S A103: Jan. 31; Epub ahead of print, 2006.
